| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| S9083 |
Global fee urgent care centers |
2,462 |
2,021 |
$245K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,972 |
2,620 |
$205K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,743 |
1,522 |
$173K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,745 |
2,400 |
$170K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,779 |
2,478 |
$169K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,128 |
2,025 |
$133K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,978 |
1,588 |
$120K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,397 |
1,237 |
$95K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
6,096 |
5,042 |
$93K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
620 |
469 |
$36K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
351 |
250 |
$30K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
461 |
373 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,328 |
1,367 |
$14K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,720 |
1,459 |
$10K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
18 |
18 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
124 |
109 |
$1K |
| 81025 |
|
557 |
505 |
$845.04 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
110 |
104 |
$695.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
73 |
58 |
$351.90 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
111 |
105 |
$350.00 |
| 99051 |
|
1,933 |
1,667 |
$314.14 |
| 90686 |
|
14 |
12 |
$94.37 |
| 86580 |
|
31 |
26 |
$52.00 |
| 81000 |
|
555 |
523 |
$33.92 |
| 81002 |
|
15 |
13 |
$8.00 |
| 90674 |
|
12 |
12 |
$0.00 |